Amiodarone use has been limited due to toxicity to various organ such as the lungs and liver. Dronedarone an analogue of amiodarone was introduced into the market as a safer option to restore sinus rhythm and reduce the rates of hospitalization in patients with paroxysmal or persistent atrial fibrillation. Adverse events(AE) reported for dronedarone include pulmonary toxicity and liver injury. The objective of the study was to assess the patterns of these AE reports and to compare the safety profile of dronedarone and amiodarone. The primary data source was the FDA Adverse Event Reporting System (FAERS) database from quarter 1, 2012 to quarter 2, 2018. Study drugs were dronedarone and amiodarone. Brand name and generic name were used to search AE reports. AEs were documented as MedDRA (Medical Dictionary for Regulatory Activities) preferred terms. Frequency distribution, trend line and histogram were analyzed and compared for amiodarone and dronedarone. Patient demographic age, sex was also analyzed and compared. 24,305 and 4,101 reports respectively were patient associated. For amiodarone, 30.5% of reports involved female, 43.5% males, and in 26% sex was not reported. For dronedarone, most reports did not include sex (36.8%), 33.9% involved females and 29.4% males. Mean age (SD) was 70.6 (4.4) years old and 68.3 (6.6) for amiodarone and dronedarone respectively. The most frequent common AE reports were dyspnea (1.82%), asthenia (1.27%) and gastro-intestinal hemorrhage (1.06%) for amiodarone and dyspnea (1.97%), and gastro-intestinal hemorrhage (1.91), asthenia (1%) was reported for dronedarone. The most frequent outcome associated with AE reports was hospitalization: 45.2% and 46.4% for amiodarone and dronedarone respectively. There were 12% death reports for amiodarone and 7.5% for dronedarone. Although dronedarone seems to have a better safety profile compared to amiodarone, therapeutic risk management of dronedarone may be warrant for post-marketing surveillance.